These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 8186129)
21. Cytokine-based therapy for melanoma: pre-clinical studies. Shurin MR; Kirkwood JM; Esche C Forum (Genova); 2000; 10(3):204-26. PubMed ID: 11007930 [TBL] [Abstract][Full Text] [Related]
22. A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Dummer R; Gore ME; Hancock BW; Guillou PJ; Grobben HC; Becker JC; Oskam R; Dieleman JP; Burg G Cancer; 1995 Feb; 75(4):1038-44. PubMed ID: 7842406 [TBL] [Abstract][Full Text] [Related]
23. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2]. Dehesa LA; Vilar-Alejo J; Valerón-Almazán P; Carretero G Actas Dermosifiliogr; 2009 Sep; 100(7):571-85. PubMed ID: 19715642 [TBL] [Abstract][Full Text] [Related]
24. [Present status and problems in the therapy of malignant melanoma]. Nakayama J Fukuoka Igaku Zasshi; 1995 Jan; 86(1):1-5. PubMed ID: 7698716 [No Abstract] [Full Text] [Related]
25. T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma. Ogawa H; Luxardi G; Kirane A; Kulkarni R; Monjazeb AM; Cheng MY; Ma C; Maverakis E J Invest Dermatol; 2018 Jun; 138(6):1442-1445. PubMed ID: 29291382 [No Abstract] [Full Text] [Related]
26. A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma. Kaufman HL; DeRaffele G; Divito J; Hörig H; Lee D; Panicali D; Voulo M Hum Gene Ther; 2001 Jul; 12(11):1459-80. PubMed ID: 11485637 [No Abstract] [Full Text] [Related]
27. A major player "gets in the act". Dudley ME J Immunother; 2012 Oct; 35(8):595-7. PubMed ID: 22996364 [No Abstract] [Full Text] [Related]
28. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Triozzi PL; Strong TV; Bucy RP; Allen KO; Carlisle RR; Moore SE; Lobuglio AF; Conry RM Hum Gene Ther; 2005 Jan; 16(1):91-100. PubMed ID: 15703492 [TBL] [Abstract][Full Text] [Related]
29. Clearing of melanoma in situ with intralesional interferon alfa in a patient with xeroderma pigmentosum. Turner ML; Moshell AN; Corbett DW; Stern JB; Roth MJ; DiGiovanna J; Horn TD; Kraemer KH Arch Dermatol; 1994 Dec; 130(12):1491-4. PubMed ID: 7986121 [No Abstract] [Full Text] [Related]
30. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875 [TBL] [Abstract][Full Text] [Related]
32. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study. Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585 [TBL] [Abstract][Full Text] [Related]
33. Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma. Osanto S; Brouwenstÿn N; Vaessen N; Figdor CG; Melief CJ; Schrier PI Hum Gene Ther; 1993 Jun; 4(3):323-30. PubMed ID: 8338879 [TBL] [Abstract][Full Text] [Related]
34. [Immunohistological study of the mechanism of cytotoxic effect against cutaneous metastatic malignant melanoma by intralesional injection with anti-monosialoganglioside mouse monoclonal antibody (MAb 202)]. Ota T; Imamura T; Hamanaka S; Nishioka K; Tai T; Kawashima I; Irie RF; Asagami C Nihon Hifuka Gakkai Zasshi; 1988 Aug; 98(9):913-22. PubMed ID: 3244169 [No Abstract] [Full Text] [Related]
35. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. Lindsey KR; Rosenberg SA; Sherry RM J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637 [TBL] [Abstract][Full Text] [Related]
36. Management of metastatic melanoma to the breast with high-dose interleukin-2 and surgical resection. Komenaka IK; DeRaffele G; Hurst-Wicker KS; Kaufman HL Breast J; 2005; 11(2):158-9. PubMed ID: 15730472 [No Abstract] [Full Text] [Related]
37. [Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma]. Pföhler C; Steinhäuser S; Wagner A; Ugurel S; Tilgen W Hautarzt; 2004 Feb; 55(2):171-5. PubMed ID: 14968328 [TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Schreiber S; Kämpgen E; Wagner E; Pirkhammer D; Trcka J; Korschan H; Lindemann A; Dorffner R; Kittler H; Kasteliz F; Küpcü Z; Sinski A; Zatloukal K; Buschle M; Schmidt W; Birnstiel M; Kempe RE; Voigt T; Weber HA; Pehamberger H; Mertelsmann R; Bröcker EB; Wolff K; Stingl G Hum Gene Ther; 1999 Apr; 10(6):983-93. PubMed ID: 10223732 [TBL] [Abstract][Full Text] [Related]
39. Intralesional interferon-alpha therapy in advanced malignant melanoma. von Wussow P; Block B; Hartmann F; Deicher H Cancer; 1988 Mar; 61(6):1071-4. PubMed ID: 3342367 [TBL] [Abstract][Full Text] [Related]
40. T cell triumph. Immunotherapy may have finally turned a corner. Martindale D Sci Am; 2003 Feb; 288(2):12-3. PubMed ID: 12561452 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]